{"url_path":"/sec/gyre/8-k/2026-06-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-023625-index.html","accession_number":"0001140361-26-023625","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-023625-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":80,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\n(d) Exhibits.\n\n \n\nEXHIBIT INDEX\n\nExhibit\n\nNo.\n\nDescription\n\n \n\n \n\n[99.1](ef20075381_ex99-1.htm)\n\nCorporate Presentation, dated June 2026\n\n \n\n \n\n104\n\nCover page interactive data file (embedded within the inline XBRL document)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its\nbehalf by the undersigned hereunto duly authorized.\n\n \n\nGYRE THERAPEUTICS, INC.\n\n \n\n \n\nDate: June 2, 2026\n\nBy:\n\n/s/ Thomas Eastling\n\n \n\nName:\n\nThomas Eastling\n\n \n\nTitle:\n\nChief Financial Officer"}